Some with severe sickle cell disease in England will now be able to access landmark CRISPR gene editing therapy, according to new health guidelines which were hailed as marking a “significant ...

to allow patients with sickle cell disease (SCD) to access its gene-edited therapy Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP). The deal comes after the National Institute for Health ...

LONDON — People in England with sickle cell disease will now be able to access the world’s first CRISPR-based medicine under a pricing and reimbursement agreement reached between U.K. health ...

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

The £1.65 million gene therapy called exa-cel, also known under the brand name Casgevy, uses a Nobel Prize-winning gene-editing technology called Crispr. Some 1,700 patients with sickle cell ...

Some with severe sickle cell disease in England will now be able to access landmark CRISPR gene editing therapy, according to new health guidelines which were hailed as marking a “significant shift” ...

London: Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease ... Vertex Pharmaceuticals and CRISPR Therapeutics will cost the ...

for the treatment of severe sickle cell disease, a life-limiting blood disorder, in older children and adults. The one-time therapy uses clustered regularly interspaced short palindromic repeat ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease ... to be licensed using gene-editing tool Crispr, which earned its inventors the ...

Yasmin Sheikh, head of policy and public affairs at Anthony Nolan, said: “This groundbreaking decision to fund the UK’s first ever Crispr-based therapy for patients with sickle cell disorder ...